Logo Image
News|Articles|April 6, 2016

Aesica Doubles Development Capacity

Aesica adds development capability at Queenborough with the opening of a new purpose-built facility.

Aesica Pharmaceuticals, a pharmaceutical contract development and manufacturing organization, announced on April 5, 2016 it has doubled its development capacity with the addition of the ability to manufacture multiple drug products up to Phase III clinical trials at its Queenborough facility.

Aesica is now able to develop and manufacture a customer product from early formulation development through clinical manufacture and commercialization.

According to a press announcement, the company’s highly potent and controlled drugs service offering has been expanded at Queenborough as a result of the new center. The company now offers full formulation and development capabilities in these specialist fields. The site handles highly potent drugs for any active up to SafeBridge Category 3, together with controlled drugs, with licenses for both schedules 2 to 4.

Source: Aesica

 

Related to this article

View more
FDA
FDA's IND Pilot Puts CMC Review First
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Read more
Quality inspector walking through processing area with stainless tanks and tablet | Image Credit: ©Surachai -stock.adobe.com
Successful Internal Audit Planning and Execution
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
Read more